Company Filing History:
2 out of 3,684 
2 out of 2,963 
Years Active: 2008
Title: Inventor Spotlight: Krishna Kodukula
Introduction
Krishna Kodukula is a notable inventor based in Princeton, NJ, known for his significant contributions to the fields of diabetes and cardiovascular disease treatment. With a total of two patents to his name, his work represents a fusion of innovative methodologies aimed at addressing pressing health concerns.
Latest Patents
Among his latest patents, one stands out as a groundbreaking method for treating diabetes. This invention describes a technique that employs an aP2 inhibitor alone or in combination with other antidiabetic agents such as metformin, glyburide, troglitazone, and insulin. The potential impact of this method lies in its ability to improve the management of Type II diabetes and related disorders.
Another significant patent by Krishna focuses on treating atherosclerosis using an aP2 inhibitor. This innovation also involves the use of a combinatory approach with antiatherosclerotic agents, including HMG CoA reductase inhibitors like pravastatin. These patents reflect his commitment to advancing medical science and improving patient outcomes in chronic diseases.
Career Highlights
Throughout his career, Krishna has worked with esteemed organizations, including Bristol Myers Squibb Company and the President and Fellows of Harvard College. His experience in these prestigious institutions has undoubtedly contributed to his innovative approaches and insights in pharmacological research.
Collaborations
In his journey as an inventor, Krishna has had the privilege of collaborating with accomplished professionals such as Jeffrey A Robl and Rex A Parker. These collaborations not only enhance the quality of his research but also foster a supportive environment for innovation in health sciences.
Conclusion
Krishna Kodukula’s contributions as an inventor highlight the critical role of innovation in addressing complex health challenges. With his impressive track record and a focus on patient-centric solutions, he continues to pave the way for future advancements in the fields of diabetes and cardiovascular treatments.